Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 42
1946 121
1947 106
1948 84
1949 120
1950 112
1951 100
1952 129
1953 149
1954 145
1955 148
1956 122
1957 145
1958 107
1959 103
1960 114
1961 109
1962 114
1963 203
1964 227
1965 221
1966 227
1967 247
1968 318
1969 302
1970 340
1971 431
1972 478
1973 442
1974 583
1975 427
1976 372
1977 354
1978 362
1979 361
1980 402
1981 400
1982 426
1983 412
1984 455
1985 512
1986 482
1987 452
1988 499
1989 509
1990 605
1991 563
1992 548
1993 515
1994 550
1995 549
1996 539
1997 556
1998 612
1999 543
2000 633
2001 616
2002 725
2003 798
2004 828
2005 857
2006 994
2007 1008
2008 1063
2009 1000
2010 1082
2011 1135
2012 1202
2013 1259
2014 1234
2015 1288
2016 1246
2017 1201
2018 1175
2019 1050
2020 499
2021 19
Text availability
Article attribute
Article type
Publication date

Search Results

36,532 results
Results by year
Filters applied: . Clear all
Page 1
Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
Froestl W, Muhs A, Pfeifer A. Froestl W, et al. J Alzheimers Dis. 2012;32(4):793-887. doi: 10.3233/JAD-2012-121186. J Alzheimers Dis. 2012. PMID: 22886028 Review.
Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or aging. ...It involves memory, attention, executive functions, perception, language, an …
Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering from Alzheimer's disease, schizophrenia, …
Piracetam and other structurally related nootropics.
Gouliaev AH, Senning A. Gouliaev AH, et al. Brain Res Brain Res Rev. 1994 May;19(2):180-222. doi: 10.1016/0165-0173(94)90011-6. Brain Res Brain Res Rev. 1994. PMID: 8061686 Review.
Nearly three decades have now passed since the discovery of the piracetam-like nootropics, compounds which exhibit cognition-enhancing properties, but for which no commonly accepted mechanism of action has been established. ...The piracetam-like nootropics
Nearly three decades have now passed since the discovery of the piracetam-like nootropics, compounds which exhibit cognition-e …
Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.
Lapin I. Lapin I. CNS Drug Rev. 2001 Winter;7(4):471-81. doi: 10.1111/j.1527-3458.2001.tb00211.x. CNS Drug Rev. 2001. PMID: 11830761 Free PMC article. Review.
Phenibut (beta-phenyl-gamma-aminobutyric acid HCl) is a neuropsychotropic drug that was discovered and introduced into clinical practice in Russia in the 1960s. It has anxiolytic and nootropic (cognition enhancing) effects. It acts as a GABA-mimetic, primarily at GABA(B) a …
Phenibut (beta-phenyl-gamma-aminobutyric acid HCl) is a neuropsychotropic drug that was discovered and introduced into clinical practice in …
Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings.
Gualtieri F. Gualtieri F. J Enzyme Inhib Med Chem. 2016;31(2):187-94. doi: 10.3109/14756366.2015.1021252. Epub 2015 Apr 1. J Enzyme Inhib Med Chem. 2016. PMID: 25831025 Review.
This paper is a review of the work of my former academic group of research in the past 15 years, in the field of cognition enhancers (also called nootropics) that identified two very potent molecules: Unifiram and Sunifiram that for a variety of reasons were not protected …
This paper is a review of the work of my former academic group of research in the past 15 years, in the field of cognition enhancers (also c …
Neuropharmacological review of the nootropic herb Bacopa monnieri.
Aguiar S, Borowski T. Aguiar S, et al. Rejuvenation Res. 2013 Aug;16(4):313-26. doi: 10.1089/rej.2013.1431. Rejuvenation Res. 2013. PMID: 23772955 Free PMC article. Review.
Several randomized, double-blind, placebo-controlled trials have substantiated BM's nootropic utility in humans. There is also evidence for potential attenuation of dementia, Parkinson's disease, and epilepsy. ...
Several randomized, double-blind, placebo-controlled trials have substantiated BM's nootropic utility in humans. There is also eviden …
Potential Therapeutics for Vascular Cognitive Impairment and Dementia.
Sun MK. Sun MK. Curr Neuropharmacol. 2018;16(7):1036-1044. doi: 10.2174/1570159X15666171016164734. Curr Neuropharmacol. 2018. PMID: 29046153 Free PMC article. Review.
CONCLUSION: Effective rescues of the memory functions might be achieved through synaptic and memory therapeutics, targeting distinct molecular signaling pathways that support the formation of new synapses and maintaining their connections. Potential therapeutic agents incl …
CONCLUSION: Effective rescues of the memory functions might be achieved through synaptic and memory therapeutics, targeting distinct molecul …
Nootropics: pharmacological properties and therapeutic use.
Gabryel B, Trzeciak HI. Gabryel B, et al. Pol J Pharmacol. 1994 Sep-Oct;46(5):383-94. Pol J Pharmacol. 1994. PMID: 7894524 Review.
This review summarizes the results of studies investigating the pharmacological properties, mechanisms of action, preclinical and clinical effects of nootropic drugs, and tries to integrate this knowledge in order to identify neuronal mechanisms underlying their therapeuti …
This review summarizes the results of studies investigating the pharmacological properties, mechanisms of action, preclinical and clinical e …
Piracetam--an old drug with novel properties?
Winnicka K, Tomasiak M, Bielawska A. Winnicka K, et al. Acta Pol Pharm. 2005 Sep-Oct;62(5):405-9. Acta Pol Pharm. 2005. PMID: 16459490 Free article. Review.
Piracetam (2-oxo-1-pyrrolidine-acetamide), the most common of the nootropic drugs, is a cyclic derivative of gamma-aminobutyric acid. The treatment with piracetam improves learning, memory, brain metabolism, and capacity. ...
Piracetam (2-oxo-1-pyrrolidine-acetamide), the most common of the nootropic drugs, is a cyclic derivative of gamma-aminobutyri
Nootropics: preclinical results in the light of clinical effects; comparison with tacrine.
Mondadori C. Mondadori C. Crit Rev Neurobiol. 1996;10(3-4):357-70. doi: 10.1615/critrevneurobiol.v10.i3-4.40. Crit Rev Neurobiol. 1996. PMID: 8978986 Review.
First, it surveys the preclinical and clinical profiles of piracetam-like nootropics. Second, the conditions under which the nootropics are active in preclinical studies are identified and analyzed with a view of finding a common denominator that could explai …
First, it surveys the preclinical and clinical profiles of piracetam-like nootropics. Second, the conditions under which the …
Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
Froestl W, Muhs A, Pfeifer A. Froestl W, et al. J Alzheimers Dis. 2014;42(1):1-68. doi: 10.3233/JAD-140402. J Alzheimers Dis. 2014. PMID: 24903780 Review.
36,532 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback